BioCryst Pharmaceuticals, Inc.  

(Public, NASDAQ:BCRX)   Watch this stock  
+0.01 (0.30%)
After Hours: 3.29 -0.07 (-2.12%)
May 26, 4:39PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.25 - 3.38
52 week 1.63 - 16.83
Open 3.35
Vol / Avg. 473,333.00/950,454.00
Mkt cap 247.61M
P/E     -
Div/yield     -
EPS -0.69
Shares 73.69M
Beta 3.01
Inst. own 77%
Aug 4, 2016
Q2 2016 BioCryst Pharmaceuticals Inc Earnings Release (Tentative) - 9:30AM EDT - Add to calendar
May 23, 2016
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting
May 19, 2016
BioCryst Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 11, 2016
BioCryst Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Q1 2016 BioCryst Pharmaceuticals Inc Earnings Call
May 5, 2016
Q1 2016 BioCryst Pharmaceuticals Inc Earnings Release
Apr 12, 2016
BioCryst Pharmaceuticals Inc at Needham Healthcare Conference
Mar 17, 2016
BioCryst Pharmaceuticals Inc at Barclays Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -473.69% -89.15%
Operating margin -395.19% -81.74%
EBITD margin - -81.36%
Return on average assets -80.53% -32.91%
Return on average equity -242.52% -69.75%
Employees 70 -
CDP Score - -


4505 Emperor Blvd Ste 200
DURHAM, NC 27703-8457
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

Officers and directors

Jon P. Stonehouse President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Thomas R. Staab II Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
Age: 70
Bio & Compensation  - Reuters
Yarlagadda S. Babu Ph.D. Senior Vice President - Drug Discovery
Age: 62
Bio & Compensation  - Reuters
Lynne Powell Senior Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
William P. Sheridan Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Alane P. Barnes Vice President, General Counsel, and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
George B. Abercrombie Non-Executive Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Director
Age: 59
Bio & Compensation  - Reuters
Robert A. Ingram Director
Age: 73
Bio & Compensation  - Reuters
Sanj K. Patel Director
Age: 45
Bio & Compensation  - Reuters